Maxcyte share news
Web14 apr. 2024 · A high-level overview of MaxCyte, Inc. (MXCT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Web8 apr. 2024 · MaxCyte, Inc. ( NASDAQ:MXCT - Get Rating) EVP Thomas M. Ross sold 6,967 shares of the stock in a transaction on Wednesday, April 5th. The shares were sold at an average price of $5.00, for a total value of $34,835.00. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Thomas M. Ross also …
Maxcyte share news
Did you know?
Web1 dag geleden · ROCKVILLE, Md., April 12, 2024 (GLOBE NEWSWIRE) — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing … WebMaxCyte, Inc. (MXCT) Loses 18.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner MaxCyte, Inc. (MXCT) is technically in oversold territory now, so the …
Web18 aug. 2024 · MaxCyte Full Year 2024 Earnings: US$0.23 loss per share (vs US$0.21 loss in FY 2024) MaxCyte ( LON:MXCT ) Full Year 2024 Results Key Financial Results Revenue: US$44.3m (up 31% from FY 2024).... WebThe MaxCyte PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 398.00p. The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
Web12 apr. 2024 · ROCKVILLE, Md., April 12, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the ... WebReleased : May 02, 2024 13:42 RNS Number : 9212D MaxCyte, Inc. 02 May 2024 MaxCyte, Inc. ("MaxCyte" or the "Company") Block Listing Application MaxCyte (AIM: MXCT, MXCR) provides notification that an application has been made to the London Stock Exchange for admission to AIM for a block
Web9 apr. 2024 · MaxCyte, Inc. ( NASDAQ:MXCT – Get Rating) CEO Douglas Doerfler sold 27,862 shares of the company’s stock in a transaction dated Thursday, April 6th. The stock was sold at an average price of ...
WebFind the latest MaxCyte, Inc financial news and headlines to keep up with the events that impact MXCT performance. ... MaxCyte Shares Jump as It Expects Growth in Life Sciences Unit in 2024 Amid COVID-19. M; Jan 20, 2024 MT Newswires. MaxCyte Shares Surge 10% as FY19 Revenue Jumped. merth andreasWebSee the most recent MaxCyte, Inc. (LSE:MXCT) share price, news, company analysis, and price history from our financial experts. merthan satterwhite virginiaWeb30 mrt. 2024 · The average price point forecasted by analysts for MaxCyte Inc. (MXCT) is $11.21, which is $6.04 above the current market price. The public float for MXCT is 98.64M, and currently, short sellers hold a 2.10% ratio of that floaft. The average trading volume of MXCT on March 30, 2024 was 562.23K shares. mertha tidwellWebMaxCyte, Inc. (MXCT) Stock Price, News, Quote & History - Yahoo Finance S&P 500 Dow 30 Nasdaq +91.09 Russell 2000 (+0.13%) Crude Oil -0.24(-0.30%) Gold (-0.13%) … merthal beachWeb22 mrt. 2024 · Fourth Quarter and Full Year 2024 Financial Results. Total revenue for the fourth quarter of 2024 was $10.2 million, compared to $8.5 million in the fourth quarter of 2024, representing growth of ... merthelinWeb18 mei 2024 · GAITHERSBURG, Md., May 18, 2024 /PRNewswire/ -- MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announces that clinical data from the first three cohorts of the... how strong is limestoneWeb4 jan. 2024 · MaxCyte, Inc. (MXCT) is a cell-based therapies and life sciences company that licenses and sells products, instruments, and technology to drug developers and biopharmaceutical companies. MXCT made its stock market debut on July 30, 2024, through an upsized initial public offering (IPO) of 23.50 million shares, priced at $13 per share. merthelin\u0027s trial leve